Please use this identifier to cite or link to this item: https://hdl.handle.net/20.500.12530/22155
Title: Long-term hazard of recurrence in HER2+ breast cancer patients untreated with anti-HER2 therapy.
Authors: 
Mesh: 
Issue Date: 16-Apr-2015
Citation: Breast Cancer Res..2015 Apr;(17):56
Abstract: Worldwide, many patients with HER2+ (human epidermal growth factor receptor 2-positive) early breast cancer (BC) do not receive adjuvant trastuzumab. Hazards of recurrence of these patients with respect to hormone receptor status of the primary tumor have not been described.
PMID: 25888246
URI: https://hdl.handle.net/20.500.12530/22155
Rights: openAccess
Appears in Collections:Fundaciones e Institutos de Investigación > IIS H. General U. Gregorio Marañón > Artículos

Files in This Item:
File Description SizeFormat 
PMC4423419.pdf739.39 kBAdobe PDFThumbnail
View/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.